The role of C5b-9 terminal complement complex in activation of the cell cycle and transcription
10.1385/IR:31:1:37 Cite this article as: Fosbrink, M., Niculescu, F. & Rus, H. Immunol Res (2005) 31: 37. doi:10.1385/IR:31:1:37 Abstract
Activation of the complement system plays an important role in innate and acquired immunity. Activation of complement and subsequent formation of C5b-9 channels on the surface of cellular membranes leads to cell lysis. When the number of channels assembled on the surface of nucleated cells is limited, C5b-9 doses not cause lysis, but instead can induce cell-cycle progression by activating signal transduction pathways, transcription factors, and key components of the cell-cycle machinery. Cell-cycle induction by C5b-9 is dependent on the activation of phosphatidylinositol 3-kinase and the ERK1 pathway in a Gi protein-dependent manner. Cell-cycle activation is regulated, in part, by activation of proto-oncogene
c-jun and AP1 DNA binding activity. C5b-9 induces sequential activation of CDK4 and CDK2, leading to G1/S-phase transition and cellular proliferation. RGC-32 is a novel gene whose expression is induced by C5b-9. RGC-32 may play a key role in cell-cycle activation by increasing cyclin B1-CDC2 activity. C5b-9-mediated cell-cycle activation plays an important role in cellular proliferation and proctection from apoptosis. Key Words C5b-9 terminal complement complex Cell cycle Proto-oncogenes Signal transduction Transcriptional regulation RGC-32 References
Shin ML, Rus HG, Niculescu FI: Membranes attack by complement: assembly and biology of the terminal complement complexes. In: Lee A, ed. Biomembranes, vol. 4. JAI Press, 1996, pp. 123–149.
Frank MM: Complement system. In: Frank MM AK, Claman HN, Unanue ER, ed. Samter's Immunologic Diseases. Little, Brown and Company, Boston, 1995, pp. 331–362.
Wallis R: Structural and functional aspects of complement activation by mannose-binding protein. Immunobiology 2002;205:433–445.
Shin ML, Carney DF Cytotoxic action and other metabolic consequences of terminal complement proteins. Prog Allergy 1988;40:44–81.
Morgan BP, Campbell AK: The recovery of human polymorphonuclear, leucocytes from sublytic complement attack is mediated by changes in intracellular free calcium. Biochem. J 1985;231:205–208.
Gee AP, Boyle MD, Borsos T: Distinction between C8-mediated and C8/C9-mediated hemogysis on the basis of independent 86Rb and hemoglobin release. J Immunol 1980;1241905–1910.
Dalmasso AP, Benson BA: Lesions, of different functional size produced by human and guinea pig complement in sheep red cell membranes. J Immunol 1981;127: 2214–2218.
Ramm LE, Whitlow MB, Mayer MM: The relationship between channel size and the number of C9 molecules in the C5b-9 complex. J Immunol 1985;134: 2594–2599.
Koski CL, Ramm LE, Hammer CH, Mayer MM, Shin ML: Cytolysis of nucleated cells by complement: cell death displays multi-hit characteristics. Proc Natl Acad Sci USA 1983;80:3816–3820.
Papadimitriou JC, Ramm LE, Drachenberg CB, Trump BF, Shin ML: Quantitative analysis of adenine nucleotides during the prelytic phase of cell death mediated by C5b-9. J Immunol 1991;147:212–217.
Morgan BP, Dankert JR, Esser AF: Recovery of human neutrophils from complement attack: removal of the membrane attack complex by endocytosis and exocytosis. J Immunol 1987;138246–253.
Carney DF, Hammer CH, Shin ML: Elimination of terminal complement complexes in the plasma membrane of nucleated cells: influence of extracellular Ca2+ and association with cellular Ca2+. J Immunol 1986;137: 263–270.
Carney DF, Lang TJ, Shin ML: Multiple gignal messengers generated by terminal complement complexes and their role in terminal complement complex elimination. J Immunol 1990;145:623–629.
Niculescu F, Rus H, Shin ML: Receptor-independent activation of guanine nucleotide-binding regulatory proteins by terminal complement complexes. J Biol Chem 1994;269:4417–4423.
Kraus S, Fishelson Z: Cell desensitization by C5b-9 complexes and calcium ionophores depends on activation of protein kinase C. Euro J Immunol 2000: 30:1272–1280.
Kraus S, Seger R, Fishelson Z: Involvement of the ERK mitogen-activated protein kinase in cell resistance to complement-mediated lysis. Clin Exp Immunol 2001; 201:366–374.
Sherr CJ: Cancer cell cycles. Science 1996;274: 1672–1677.
Smit VA, Medema RH: Checking out the G(2)/M transition. Biochim Biophys Acta 2001;1519:1–12.
van den Heuvel S, Harlow E: Distinct roles for cyclin-dependent kinases in cell cycle control. Science 1993;262:2050–2054.
Rus HG, Niculescu FI, Shin ML: Role of the C5b-9 complement complex in cell cycle and apoptosis. Immunol Rev 2001;180:49–55.
Niculescu F, Badea T, Rus H: Sublytic C5b-9 induces proliferation of human aortic smooth muscle cells: role of mitogen activated protein kinase and phosphatidylinositol 3-kinase. Atherosclerosis 1999;142:47–56.
Dashiell SM, Rus H, Koski CL: Ternimal complement complexes concomitantly stimulate proliferation and rescue of Schwann cells from apoptosis. Glia 2000; 30:187–198.
Niculescu F, Hila S Fosbrink M, et al.: Endothelial cell proliferation induced by sublytic C5b-9 requires the activation of p70S6 kinase through a mechanism involving the G-protein dependent activation of phosphatidylinositol 3-kinase. Int Immunopharmacol 2002;318:1219A.
Rus HG, Niculescu F, Shin ML: Sublytic complement attack induces cell cycle in oligodendrocytes. J Immunol 1996;156:4892–900.
Rus H, Niculescu F, Badea T, Shin ML: Terminal complement complexes induce cell cycle entry in oligodendrocytes through mitogen activated protein kinase pathway. Immunopharmacology 1997;38:177–187.
Furukawa Y, Piwnica-Worms H, Ernst TJ, Kanakura Y, Griffin JD: cdc2 gene expression at the G1 to S transition in human T lymphocytes. Science 1990;250:805–808.
Marraccino RL, Firpo EJ, Robert JM, Activation of the p34CDC2 protein kinase at the start of S phase in the human cell cycle. Mol Biol Cell 1992;3:389–401.
Moore JD, Kirk JA, Hunt T: Unmasking the S- phase-promoting potential of cyclin B1. Science 2003;300: 987–990.
Ortega S, Prieto I, Odajima J, et al.: Cyclin-dependent kinase 2 is essential for meiosis but not for mitotic cell division in mice. Nat Genet 2003;35:25–31.
Shankland SJ, Pippin JW, Couser WG: Complement (C5b-9) induces glomerular epithelial cell DNA synthesis but not proliferation in vitro. Kidney Int 1999; 56:538–548.
Pippin JW, Durvasula R, Petermann A, Hiromura K, Couser WG, Shankland SJ: DNA damage is a novel response to sublytic complement C5b-9-induced injury in podocytes. J Clin Invest 2003;111:877–885.
Badea TC, Niculescu FI, Soane L, Shin ML, Rus H: Molecular cloning and characterization of RGC-32, a novel gene induced by complement activation in oliogo-dendrocytes. J Biol Chem 1998;273:26977–26981.
Badea T, Niculescu F, Soane L, et al.: RGC-32 increases p34CDC2 kinase activity and entry of aortic smooth muscle cells into S-phase. J Biol Chem 2002;277: 502–508.
Halperin JA, Taratuska A, Nicholson-Weller A: Terminal complement complex C5b-9 stimulates mitogenesis in 3T3 cells. J Clin Invest 1993;91:1974–1978.
Benzaquen LR, Nicholson-Weller A, Halperin JA: Terminal complement proteins C5b-9 release basic fibroblast growth factor and platelet-derived growth factor from endothelial cells. J Exp Med 1994;179: 985–992.
Zwaka TP, Torzewski J, Hoeflich A, et al.: The terminal complement complex inhibits apoptosis in vascular smooth muscle cells by activating an autocrine IGF-1 loop. Faseb J 2003;17:1346–1348.
Mason JC, Lidington EA, Ahmad SR, Haskard DO: bFGF and VEGF synergistically enhance endothelial cytoprotection via decay-accelerating factor induction. Am J Physiol Cell Physiol 2002;282:C578–587.
Lublin DM, Atkinson JP: Decay-accelerating factor: biochemistry, molecular biology, and function. Annu Rev Immunol 1989;7:35–58.
Johnson GL, Lapadat R: Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 2002;298:1911–1912.
Tapon N, Moberg KH, Hariharan IK: The coupling of cell growth to the cell cycle. Curr Opin Cell Biol 2001;13:731–737.
Peng H, Takano T, Papillon J, Bijian K, Khadir A, Cybulsky AV: Complement activates the c-Jun N-terminal kinase/stress-activated protein kinase in glomerular epithelial cells. J Immunol 2002;169:2594–2601.
Niculescu F, Rus H, van Biesen T, Shin ML: Activation of Ras and mitogen-activated protein kinase pathway by terminal complement complexes is G protein dependent. J Immunol 1997;158:4405–4412.
Aoudjit L, Stanciu M, Li H, Lemay S, Takano T: p38 mitogen-activated protein kinase protects glomerular epithelial cells from complement-mediated cell injury. Am J Physiol Renal Physiol 2003;285:F765–774.
Niculescu F, Hila S, Fosbrink M, Soane L, Rus H: Sublytic C5b-9 induces translational activation in human aortic endothelial cells. Role of p70 S6 kinase. Mol Immunol 2001;2–3:113.
Darnell JE, Jr.: The JAK-STAT pathway: summary of initial studies and recent advances. Recent Prog Horm Res 1996;51:391–403; discussion 403–404.
Darnell JE, Jr.: STATs and gene regulation. Science 1997;277:1630–1635.
Niculescu F, Soane L, Badea T, Shin M, Rus H: Tyrosine phosphorylation and activation of Janus kinase 1 and STAT3 by sublytic C5b-9 complement complex in aortic endothelial cells. Immunopharmacology 1999;42: 187–193.
Treisman R: Regulation of transcription by MAP kinase cascades. Curr Opin Cell Biol 1996;8:205–215.
Murphy LO, MacKeigan JP, Blenis J: A network of immediate early gene products propagates subtle differences in mitogen-activated protein kinase signal amplitude and duration. Mol Cell Biol 2004;24:144–153.
Shaulian E, Karin M: AP-1 as a regulator of cell life and death. Nat Cell Biol 2002;4:E131–136.
Lang TJ, Badea TC, Wade R, Shin ML: Sublytic terminal complement attack on myotubes decreases the expression of mRNAs encoding muscle-specific proteins. J Neurochem 1997;68:1581–1589.
Badea TD, Park JH, Soane L, et al.: Sublytic terminal complement attack induces c-fos transcriptional activation in myotubes. J Neuroimmunol 2003;142:58–66.
Kilgore KS, Schmid E, Shanley TP, et al.: Sublytic concentrations of the membrane attack complex of complement induce endothelial interleukin-8 and monocyte chemoattaractant protein-1 through nuclear factor-kappa B activation. Am J Pathol 1997;150:2019–2031.
Viedt C, Hansch GM, Brandes RP, Kubler W, Kreuzer J: The terminal complement complex C5b-9 stimulates interleukin-6 production in human smooth muscle cells through activation of transcription factors NF-kappa B and AP-1. Faseb J 2000;14:2370–2372.
Dashiell SM, Koski CL: Sublytic terminal complement complexes decrease PO Gene expression in Schwann cells. J Neurochem 1999;73:2321–2330.